Dyskinesias and tolerance induced by chronic treatment with a D1 agonist administered in pulsatile or continuous mode to not correlate with changes of putaminal D1 receptors in drug-naive MPTP monkeys
Identifieur interne : 003E98 ( Main/Exploration ); précédent : 003E97; suivant : 003E99Dyskinesias and tolerance induced by chronic treatment with a D1 agonist administered in pulsatile or continuous mode to not correlate with changes of putaminal D1 receptors in drug-naive MPTP monkeys
Auteurs : M. Goulet [Canada] ; R. Grondin ; P. J. Blanchet ; P. J. Bedard ; T. Di Paolo [Canada]Source :
- Brain research [ 0006-8993 ] ; 1996.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Singe.
English descriptors
- KwdEn :
- 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine, Agonist, Animal, Animals, Benzazepines (blood), Benzazepines (pharmacology), Catecholamines (metabolism), D1 Dopamine receptor, Dopamine Agonists (blood), Dopamine Agonists (pharmacology), Drug Administration Schedule, Drug Tolerance, Dyskinesia, Dyskinesia, Drug-Induced (etiology), Experimental disease, Female, Infusion Pumps, Implantable, Injections, Subcutaneous, Macaca fascicularis, Monkey, Motor Activity (drug effects), Neurotoxin, Parkinson Disease, Secondary (chemically induced), Parkinson disease, Putamen (drug effects), Putamen (metabolism), Receptors, Dopamine D1 (agonists), Tolerance.
- MESH :
- chemical , agonists : Receptors, Dopamine D1.
- chemical , blood : Benzazepines, Dopamine Agonists.
- chemical , metabolism : Catecholamines.
- chemical , pharmacology : Benzazepines, Dopamine Agonists.
- chemical : 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
- chemically induced : Parkinson Disease, Secondary.
- drug effects : Motor Activity, Putamen.
- etiology : Dyskinesia, Drug-Induced.
- metabolism : Putamen.
- Animals, Drug Administration Schedule, Drug Tolerance, Female, Infusion Pumps, Implantable, Injections, Subcutaneous, Macaca fascicularis.
Abstract
Nine monkeys (Macaca fascicularis) were rendered parkinsonian after intravenous administration of the toxin MPTP. Three of these animals received pulsatile administration of the D1 receptor agonist SKF 82958 (1 mg/kg, three times daily) while three were treated by continuous infusion via an osmotic mini-pump with SKF 82958 (at an equivalent amount daily) for 29 days. Untreated MPTP as well as healthy control animals were also studied. Relief of parkinsonian symptoms was observed in the three animals of the pulsatile group. However, dyskinesia occurred in two monkeys which had striatal dopamine depletion of > 99% compared to the non-dyskinetic animal slightly less denervated (94%). Monkeys receiving continuous SKF 82958 showed no anti-parkinsonian effect and no dyskinesia. All monkeys from the pulsatile and continuous group had measurable amount of plasma SKF 82958 as assayed by HPLC with electrochemical detection. In the putamen of all SKF 82958-treated monkeys, Bmax of D1 receptors labeled with [3H]SCH 23390 were increased versus untreated MPTP-monkeys with no change in Kd. In contrast, a decrease D1 receptor density was observed in the nucleus accumbens of untreated MPTP monkeys versus controls and this was not corrected with either pulsatile or continuous SKF 82958 treatments. D2 receptor density measured with [3H]spiperone binding was increased in the posterior putamen of SKF 82958-treated monkeys whereas no change was observed in the accumbens compared to control animals. Hence, tolerance with the continuous administration of a Dl agonist is not associated with a decrease of putaminal D1 or D2 receptor densities and dyskinesia could not be specifically associated with an increase of putaminal Dl receptors.
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: 000F32
- to stream PascalFrancis, to step Curation: 000F91
- to stream PascalFrancis, to step Checkpoint: 000E28
- to stream Main, to step Merge: 004594
- to stream PubMed, to step Corpus: 001875
- to stream PubMed, to step Curation: 001875
- to stream PubMed, to step Checkpoint: 001875
- to stream Ncbi, to step Merge: 002543
- to stream Ncbi, to step Curation: 002543
- to stream Ncbi, to step Checkpoint: 002543
- to stream Main, to step Merge: 004370
- to stream Main, to step Curation: 003E98
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Dyskinesias and tolerance induced by chronic treatment with a D1 agonist administered in pulsatile or continuous mode to not correlate with changes of putaminal D1 receptors in drug-naive MPTP monkeys</title><author><name sortKey="Goulet, M" sort="Goulet, M" uniqKey="Goulet M" first="M." last="Goulet">M. Goulet</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>School of Pharmacy, Laval University and Department of Molecular Endocrinology, Laval University Medical Center</s1><s2>Ste-Foy, Québec G1V 4G2</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Ste-Foy, Québec G1V 4G2</wicri:noRegion></affiliation></author><author><name sortKey="Grondin, R" sort="Grondin, R" uniqKey="Grondin R" first="R." last="Grondin">R. Grondin</name></author><author><name sortKey="Blanchet, P J" sort="Blanchet, P J" uniqKey="Blanchet P" first="P. J." last="Blanchet">P. J. Blanchet</name></author><author><name sortKey="Bedard, P J" sort="Bedard, P J" uniqKey="Bedard P" first="P. J." last="Bedard">P. J. Bedard</name></author><author><name sortKey="Di Paolo, T" sort="Di Paolo, T" uniqKey="Di Paolo T" first="T." last="Di Paolo">T. Di Paolo</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>School of Pharmacy, Laval University and Department of Molecular Endocrinology, Laval University Medical Center</s1><s2>Ste-Foy, Québec G1V 4G2</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Ste-Foy, Québec G1V 4G2</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">96-0307868</idno><date when="1996">1996</date><idno type="stanalyst">PASCAL 96-0307868 INIST</idno><idno type="RBID">Pascal:96-0307868</idno><idno type="wicri:Area/PascalFrancis/Corpus">000F32</idno><idno type="wicri:Area/PascalFrancis/Curation">000F91</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">000E28</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000E28</idno><idno type="wicri:doubleKey">0006-8993:1996:Goulet M:dyskinesias:and:tolerance</idno><idno type="wicri:Area/Main/Merge">004594</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:8782872</idno><idno type="wicri:Area/PubMed/Corpus">001875</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001875</idno><idno type="wicri:Area/PubMed/Curation">001875</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001875</idno><idno type="wicri:Area/PubMed/Checkpoint">001875</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001875</idno><idno type="wicri:Area/Ncbi/Merge">002543</idno><idno type="wicri:Area/Ncbi/Curation">002543</idno><idno type="wicri:Area/Ncbi/Checkpoint">002543</idno><idno type="wicri:doubleKey">0006-8993:1996:Goulet M:dyskinesias:and:tolerance</idno><idno type="wicri:Area/Main/Merge">004370</idno><idno type="wicri:Area/Main/Curation">003E98</idno><idno type="wicri:Area/Main/Exploration">003E98</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Dyskinesias and tolerance induced by chronic treatment with a D1 agonist administered in pulsatile or continuous mode to not correlate with changes of putaminal D1 receptors in drug-naive MPTP monkeys</title><author><name sortKey="Goulet, M" sort="Goulet, M" uniqKey="Goulet M" first="M." last="Goulet">M. Goulet</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>School of Pharmacy, Laval University and Department of Molecular Endocrinology, Laval University Medical Center</s1><s2>Ste-Foy, Québec G1V 4G2</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Ste-Foy, Québec G1V 4G2</wicri:noRegion></affiliation></author><author><name sortKey="Grondin, R" sort="Grondin, R" uniqKey="Grondin R" first="R." last="Grondin">R. Grondin</name></author><author><name sortKey="Blanchet, P J" sort="Blanchet, P J" uniqKey="Blanchet P" first="P. J." last="Blanchet">P. J. Blanchet</name></author><author><name sortKey="Bedard, P J" sort="Bedard, P J" uniqKey="Bedard P" first="P. J." last="Bedard">P. J. Bedard</name></author><author><name sortKey="Di Paolo, T" sort="Di Paolo, T" uniqKey="Di Paolo T" first="T." last="Di Paolo">T. Di Paolo</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>School of Pharmacy, Laval University and Department of Molecular Endocrinology, Laval University Medical Center</s1><s2>Ste-Foy, Québec G1V 4G2</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Ste-Foy, Québec G1V 4G2</wicri:noRegion></affiliation></author></analytic><series><title level="j" type="main">Brain research</title><title level="j" type="abbreviated">Brain res.</title><idno type="ISSN">0006-8993</idno><imprint><date when="1996">1996</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Brain research</title><title level="j" type="abbreviated">Brain res.</title><idno type="ISSN">0006-8993</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine</term><term>Agonist</term><term>Animal</term><term>Animals</term><term>Benzazepines (blood)</term><term>Benzazepines (pharmacology)</term><term>Catecholamines (metabolism)</term><term>D1 Dopamine receptor</term><term>Dopamine Agonists (blood)</term><term>Dopamine Agonists (pharmacology)</term><term>Drug Administration Schedule</term><term>Drug Tolerance</term><term>Dyskinesia</term><term>Dyskinesia, Drug-Induced (etiology)</term><term>Experimental disease</term><term>Female</term><term>Infusion Pumps, Implantable</term><term>Injections, Subcutaneous</term><term>Macaca fascicularis</term><term>Monkey</term><term>Motor Activity (drug effects)</term><term>Neurotoxin</term><term>Parkinson Disease, Secondary (chemically induced)</term><term>Parkinson disease</term><term>Putamen (drug effects)</term><term>Putamen (metabolism)</term><term>Receptors, Dopamine D1 (agonists)</term><term>Tolerance</term></keywords><keywords scheme="MESH" type="chemical" qualifier="agonists" xml:lang="en"><term>Receptors, Dopamine D1</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Benzazepines</term><term>Dopamine Agonists</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Catecholamines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Benzazepines</term><term>Dopamine Agonists</term></keywords><keywords scheme="MESH" type="chemical" xml:lang="en"><term>1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Parkinson Disease, Secondary</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Motor Activity</term><term>Putamen</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Dyskinesia, Drug-Induced</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Putamen</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Drug Administration Schedule</term><term>Drug Tolerance</term><term>Female</term><term>Infusion Pumps, Implantable</term><term>Injections, Subcutaneous</term><term>Macaca fascicularis</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Tolérance</term><term>Agoniste</term><term>Récepteur dopaminergique D1</term><term>Neurotoxine</term><term>Dyskinésie</term><term>Animal</term><term>Pathologie expérimentale</term><term>Parkinson maladie</term><term>Singe</term><term>MPTP</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Singe</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Nine monkeys (Macaca fascicularis) were rendered parkinsonian after intravenous administration of the toxin MPTP. Three of these animals received pulsatile administration of the D<sub>1</sub> receptor agonist SKF 82958 (1 mg/kg, three times daily) while three were treated by continuous infusion via an osmotic mini-pump with SKF 82958 (at an equivalent amount daily) for 29 days. Untreated MPTP as well as healthy control animals were also studied. Relief of parkinsonian symptoms was observed in the three animals of the pulsatile group. However, dyskinesia occurred in two monkeys which had striatal dopamine depletion of > 99% compared to the non-dyskinetic animal slightly less denervated (94%). Monkeys receiving continuous SKF 82958 showed no anti-parkinsonian effect and no dyskinesia. All monkeys from the pulsatile and continuous group had measurable amount of plasma SKF 82958 as assayed by HPLC with electrochemical detection. In the putamen of all SKF 82958-treated monkeys, B<sub>max</sub> of D1 receptors labeled with [<sup>3</sup>H]SCH 23390 were increased versus untreated MPTP-monkeys with no change in K<sub>d</sub>. In contrast, a decrease D1 receptor density was observed in the nucleus accumbens of untreated MPTP monkeys versus controls and this was not corrected with either pulsatile or continuous SKF 82958 treatments. D2 receptor density measured with [<sup>3</sup>H]spiperone binding was increased in the posterior putamen of SKF 82958-treated monkeys whereas no change was observed in the accumbens compared to control animals. Hence, tolerance with the continuous administration of a Dl agonist is not associated with a decrease of putaminal D1 or D2 receptor densities and dyskinesia could not be specifically associated with an increase of putaminal Dl receptors.</div></front></TEI><affiliations><list><country><li>Canada</li></country></list><tree><noCountry><name sortKey="Bedard, P J" sort="Bedard, P J" uniqKey="Bedard P" first="P. J." last="Bedard">P. J. Bedard</name><name sortKey="Blanchet, P J" sort="Blanchet, P J" uniqKey="Blanchet P" first="P. J." last="Blanchet">P. J. Blanchet</name><name sortKey="Grondin, R" sort="Grondin, R" uniqKey="Grondin R" first="R." last="Grondin">R. Grondin</name></noCountry><country name="Canada"><noRegion><name sortKey="Goulet, M" sort="Goulet, M" uniqKey="Goulet M" first="M." last="Goulet">M. Goulet</name></noRegion><name sortKey="Di Paolo, T" sort="Di Paolo, T" uniqKey="Di Paolo T" first="T." last="Di Paolo">T. Di Paolo</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003E98 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003E98 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= Pascal:96-0307868
|texte= Dyskinesias and tolerance induced by chronic treatment with a D1 agonist administered in pulsatile or continuous mode to not correlate with changes of putaminal D1 receptors in drug-naive MPTP monkeys
}}
| This area was generated with Dilib version V0.6.29. |  |